Abstract: An operating device contains a sensor surface, a signal generator for providing a control signal with a predetermined frequency for the sensor surface, an evaluation device which is configured to provide a sensor signal which is dependent on the capacitance of the sensor surface, and a control facility. In this process, the control facility is configured to determine measuring noise on the evaluation device at different frequencies and to select the frequency of the control signal in order to determine the sensor signal as a function of the determined measuring noise.

Abstract: A cable sealing plug includes a cable pass through opening extending through the cable sealing plug in an axial direction, a compression seal extending around the cable pass through opening, and a locking part having a locking system. The compression seal is transferable to a compressed state in which an inner diameter of the compression seal is smaller than a predetermined cable diameter of an electric cable extending through the cable pass through opening. The locking part and the compression seal are formed as a unitary component.

Abstract: An electrical plug device includes a connector housing pluggable with a mating housing, a connection aid engageable with the mating housing, a position assurance element held at the connector housing and displaceable from an open position to a securing position, and a blocking mechanism. The connection aid is movable from a plugging position to a holding position. The connector housing in the plugging position is connectable to the mating housing. The mating housing in the holding position is held at the connector housing. The connection aid in the open position is movable from the plugging position to the holding position and in the securing position is fixated in the holding position. The blocking mechanism blocks the position assurance element in the open position and has a release element with which the blocking mechanism is released in a state of the connector housing and the mating housing being plugged together.

Abstract: It was found that finafloxacin has a high solubility in the presence of Tris. Such solubility is significantly higher than in the presence of other compounds typically used as buffers (e.g. phosphate buffer). The observed significant increase in solubility of finafloxacin in compositions comprising Tris is further advantageously accompanied by a long term stability of such solutions. Tris is therefore to be regarded as a specific tool to considerably enhance the solubility of finafloxacin in solutions. By preparing compositions comprising Tris it is possible to dissolve finafloxacin in such an amount therein that these compositions can effectively be used as parenteral compositions for the treatment of bacterial infections.

Abstract: It was found that finafloxacin eradicates pathogens from patients suffering from bacterial infections like urinary tract infections and pyelonephritis more quickly than other fluoroquinolones regularly used for the treatment of these patients. Due to the efficacy of finafloxacin reduced treatment durations without increasing the daily dosage of finafloxacin and at the same time no or shorter stays in hospital are realizable, thus improving patient convenience and significantly lowering the costs of hospitalization and treatment. Reduced hospitalization periods do also clearly reduce the risk of nosocomial infections and of generating drug-resistant strains through extended therapy. The inventive treatment regimens comprise an oral finafloxacin administration for 1-5 days or a parenteral finafloxacin administration for 1-5 days for use in the treatment of a complicated urinary tract infection or pyelonephritis. However, a prior short parenteral administration of finafloxacin (e.g.

Abstract: It was found that finafloxacin eradicates pathogens from patients suffering from bacterial infections like urinary tract infections and pyelonephritis more quickly than other fluoroquinolones regularly used for the treatment of these patients. Due to the efficacy of finafloxacin reduced treatment durations without increasing the daily dosage of finafloxacin and at the same time no or shorter stays in hospital are realizable, thus improving patient convenience and significantly lowering the costs of hospitalization and treatment. Reduced hospitalization periods do also clearly reduce the risk of nosocomial infections and of generating drug-resistant strains through extended therapy. The inventive treatment regimens comprise an oral finafloxacin administration for 1-5 days or a parenteral finafloxacin administration for 1-5 days for use in the treatment of a complicated urinary tract infection or pyelonephritis. However, a prior short parenteral administration of finafloxacin (e.g.

Abstract: It was found that finafloxacin has a high solubility in the presence of Tris. Such solubility is significantly higher than in the presence of other compounds typically used as buffers (e.g. phosphate buffer). The observed significant increase in solubility of finafloxacin in compositions comprising Tris is further advantageously accompanied by a long term stability of such solutions. Tris is therefore to be regarded as a specific tool to considerably enhance the solubility of finafloxacin in solutions. By preparing compositions comprising Tris it is possible to dissolve finafloxacin in such an amount therein that these compositions can effectively be used as parenteral compositions for the treatment of bacterial infections.

Abstract: Novel crosslinkable compositions are provided and are based on thermoplastic polymers and elastomers, these compositions comprising, as crosslinking system, specific organic salts of metal ions. Ionically crosslinked thermoplastic elastomers can be obtained therefrom and have excellent physical properties, high-temperature resistance extending above 150° C., and also oil resistance. They can be used for production of moldings.

Abstract: A nucleic acid molecule encoding the gilvocarcin V gene cluster and subunits thereof. Recombinant vectors and host cells comprising a nucleic acid compound encoding the gilvocarcin V gene cluster or subunits thereof. Host cells comprising recombinant vectors encoding the gilvocarcin polyketide synthase and gilvocarcin post-PKS modifying enzymes from Streptomyces griseoflavus can be used to produce gilvocarcin and functional gilvocarcin mutants, analogs and derivatives thereof with application as antibiotics, anticancer agents, immunosuppressants, antivirals, and neuroprotective agents.

Abstract: Novel crosslinkable compositions are provided and are based on thermoplastic polymers and elastomers, these compositions comprising, as crosslinking system, specific organic salts of metal ions. Ionically crosslinked thermoplastic elastomers can be obtained therefrom and have excellent physical properties, high-temperature resistance extending above 150° C., and also oil resistance. They can be used for production of mouldings.

Abstract: A nucleic acid molecule encoding the gilvocarcin V gene cluster and subunits thereof. Recombinant vectors and host cells comprising a nucleic acid compound encoding the gilvocarcin V gene cluster or subunits thereof. Host cells comprising recombinant vectors encoding the gilvocarcin polyketide synthase and gilvocarcin post-PKS modifying enzymes from Streptomyces griseoflavus can be used to produce gilvocarcin and functional gilvocarcin mutants, analogs and derivatives thereof with application as antibiotics, anticancer agents, immunosuppressants, antivirals, and neuroprotective agents.